The Liposome Company, Inc.

Celator Pharmaceuticals, Inc.

Transave Limited

The Lipsome Company, Inc.

Other

Elan Pharmaceuticals, Inc.

Elan Pharmaceuticalstechnologies, Inc.

The Liposme Company, Inc.

Cephalon, Inc.

Zeneus Pharma Limited

Weiner, Alan L.

Estis, Leonard F.

Bally, Marcel B.

Madden, Thomas D.

Cullis, Pieter R.

Andrew S Janoff

Eric G Mayhew

Alan L Weiner

Imran Ahmad

J Craig Franklin

Mircea C Popescu

Suresh K Bhatia

Paul A Tremblay

Shaukat Ali

Marcel B Bally

Lois E Bolcsak

Marc J Ostro

Pieter Rutter Cullis

Michael W Fountain

Sharma R Minchey

Lawrence D Mayer

Robert P Lenk

Patrick L Ahl

Christine E Swenson

Walter R Perkins

Paul R Meers

Michael J Hope

Thomas D Madden

Richard S Ginsberg

Donna J Cabral-Lilly

Lawrence T Boni

Paul A Harmon

Charles Pak

Carl R Alving

Paul Tardi

Murray Webb

Troy Harasym

Michael V Bergamini

Regina L Jablonski

Hugh P Schieren

Tong Shangguan

Clifford Shew

Robert L Suddith

Steven J Weiss

Gil Koehane

Yong Wei

Soumendu Bhattacharya

Colin P Tilcock

Joyce Rauch

John J Kearns

Robert J Klimchak

Ravi K Erukulla

Anthony G Durning

Sol M Gruner

Gerald Weissmann

Leonard Estis

David F Eierman

James R Seibold

Ravi Erukulla

Thomas S Davis

Lynn D Keyes

Christine Swenson

Marie S Recine

Jo Ann Jedrusiak

Leonard F Estis

Joel B Portnoff

Michelle L Tomsho

Theodore F Taraschi

Elaine Chan

Paul S Tremblay

John Redman

Micrea C Popescu

Kathy A Stewart

Donald Hirsh

Xingong Li

Lois E Bolscak

Robert A Reed

Arthur Louie

Lawrence Mayer

Carl L Alving

Joel Portnoff

Fountain Michael W

Huge P Schieren

Colin Ps Tilcock

Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.

Compositions for delivery of drug combinations

Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.

Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors.

Fixed ratio drug combination treatments for solid tumors

This invention provides a method to prepare liposome-encapsulated bioactive agents such as nucleic acids, comprising complexation of the bioactive agents in reverse micelles prior to forming liposomes, as well as methods of using the liposomes so formed and formulations to deliver nucleic acids to cells.

Encapsulation of bioactive complexes in liposomes

A liposome including a fusogenic liposome, a linking moiety and a targeting moiety. The fusogenic liposome is a lipid bilayer encapsulating contents. The linking moiety is electrostatically bound to the lipid bilayer, and the targeting moiety is covalently bound to the linking moiety. The liposome may also include a stabilizing moiety interposed between the linking and targeting moieties, and covalently bound to both. Alternatively, the stabilizing and targeting moieties may be covalently bound to separate linking moieties, the linking moieties being electrostatically bound to the lipid bilayer.

Modular targeted liposomal delivery system

Described herein are liposomes containing etherlipids of the formula:as well as a phosphatidylcholine, a sterol, and a headgroup-derivatized lipid. These liposomes are useful in a variety of therapeutic regimens, including the treatment of cancers and inflammatory disorders.

Etherlipid-containing multiple lipid liposomes

A liposome having a lipid bilayer, where the lipid bilayer includes either the L or D stereoisomer of an ether lipid or a non-equal mixture of both. Most preferably the liposome also comprises (a) an underivatized phosphatidylcholine; (b) a sterol; (c) about 5-20 mole % of a phosphatidylethanolamine linked to a dicarboxylic acid at the ethanolamine group of the phosphatidylethanolamine, and (d) greater than about 10 mole % to less than about 30 mole % of either the L or D stereoisomer of an ether lipid. The liposome may be used as an anti-cancer or anti-inflammatory agent.

D and L etherlipid stereoisomers and liposomes

This invention provides vehicles capable of delivering high concentrations of poorly hydrophilic/poorly lipophilic compounds to animals, by combining compounds having biocompatible hydrophobic domains with conjugates having both hydrophobic and hydrophilic regions. Such formulations are suitable for a number of uses in animals, particularly the administration thereto of high concentrations of therapeutically useful compound, without an undue level of side effects.

Particulate formulations

Provided herein is a taxane having a hydrocarbon attached at the 2&prime; and/or 7 positions, the hydrocarbon's alpha position being occupied by a &ldquo;hydrolysis-promoting group&rdquo; (&ldquo;HPG&rdquo;). In one embodiment, the hydrolysis promoting group is stereospecifically attached to the &agr;-carbon of the hydrophobic taxane. The Substitution of an HPG for the methylene unit ordinarily occupying the alpha position allows for enhanced in vivo hydrolysis of the hydrocarbon-taxane bond, and hence, for enhanced taxane therapeutic activity. Also provided herein are taxane-containing compositions, and methods of administering taxanes to animals, including those afflicted with cancers or inflammatory diseases.

Hydrolysis-promoting hydrophobic taxane derivatives

Methods and compositions are described for nonliposomal lipid complexes in association with toxic hydrophobic drugs such as the polyene antibiotic amphotericin B. Lipid compositions are preferably a combination of the phospholipids dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG) in about a 7:3 mole ratio. The lipid complexes contain a bioactive agent, and may be made by a number of procedures, at high drug:lipid ratios. These compositions of high drug:lipid complexes (HDLCs) may be administered to mammals such as humans for the treatment of infections, with substantially equivalent or greater efficacy and reduced drug toxicities as compared to the drugs in their free form. Also disclosed is a novel liposome-loading procedure, which may also be used in the formation of the HDLCs.

Methods of preparing low-toxicity drug-lipid complexes

Provided herein is a taxane having a hydrocarbon attached at the 2&prime; and/or 7 positions, the hydrocarbon's alpha position being occupied by a &ldquo;hydrolysis-promoting group&rdquo; (&ldquo;HPG&rdquo;). In one embodiment, the hydrolysis promoting group is stereospecifically attached to the a-carbon of the hydrophobic taxane. The Substitution of an HPG for the methylene unit ordinarily occupying the alpha position allows for enhanced in vivo hydrolysis of the hydrocarbon-taxane bond, and hence, for enhanced taxane therapeutic activity. Also provided herein are taxane-containing compositions, and methods of administering taxanes to animals, including those afflicted with cancers or inflammatory diseases.

Methods and compositions are described for the preparation of bioactive agents entrapped in lipid vesicles the bilayers of which comprise a salt form of an organic acid derivative of a sterol, such as the tris-salt form of a sterol hemisuccinate, and to bompositions comprising a mixtue of tris(hydroxymethyl)aminomethane salt of cholesteryl hemisuccinate with either an antifungal compound or a peptide. These compositions have various applications in vivo.

Steroidal liposomes

Growing community of inventors

Yardley, PA, United States of America

Andrew S Janoff